re 1... biotech assets can become stranded. ie it is very expensive, even once you get through P3 to get the asset approved. This is what happened with Brickell and SB. Look at their mkt cap and their inability to raise capital given their cost base and you will see they didn't have the ability to fund SB through to approval. So better off to sell it, take a royalty and let BOT fund the approval. It cost BOT millions just to file the application for apporval
2. Kaken pays royalty to Brickell and part of this flows to BOT
3. BOT owns SB
BOT - Anything but charting, page-3459
-
- There are more pages in this discussion • 5,567 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.015(4.62%) |
Mkt cap ! $606.3M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 34.5¢ | 32.5¢ | $2.336M | 6.962M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 241454 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 50957 | 3 |
View Market Depth
| Last trade - 15.05pm 03/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |